{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:33:54Z","timestamp":1792812834611,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.nmd.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T11:45:00Z","timestamp":1655811900000},"page":"664-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-8504","authenticated-orcid":false,"given":"Marta","family":"Caballero-\u00c1vila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"\u00c1lvarez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Moga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Turon-Sans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reyes-Leiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1428-1072","authenticated-orcid":false,"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.06.006_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nmd.2022.06.006_bib0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11940-020-00632-6","article-title":"Myasthenia gravis treatment updates","volume":"22","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.nmd.2022.06.006_bib0003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.06.006_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.nmd.2022.06.006_bib0005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2022.06.006_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.nmd.2022.06.006_bib0007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2022.06.006_bib0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2022.06.006_bib0009","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.nmd.2022.06.006_bib0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: Hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.nmd.2022.06.006_bib0011","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357900701809068","article-title":"Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma","volume":"26","author":"Walker","year":"2008","journal-title":"Cancer Invest"},{"issue":"9","key":"10.1016\/j.nmd.2022.06.006_bib0012","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: Long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.nmd.2022.06.006_bib0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.nmd.2022.06.006_bib0014","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De la","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2022.06.006_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.nmd.2022.06.006_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"20","key":"10.1016\/j.nmd.2022.06.006_bib0017","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2022.06.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinno","year":"2018","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"issue":"6","key":"10.1016\/j.nmd.2022.06.006_bib0019","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2022.06.006_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jbspin.2010.09.016","article-title":"Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology","volume":"78","author":"Samson","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.nmd.2022.06.006_bib0021","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.06.006_bib0022","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2022.06.006_bib0023","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2022.06.006_bib0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.06.006_bib0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10.1016\/j.nmd.2022.06.006_bib0026","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.nmd.2022.06.006_bib0027","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/ene.14391","article-title":"Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study","volume":"27","author":"Dos Santos","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2022.06.006_bib0028","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-444-63849-6.00010-4","article-title":"Progressive multifocal leukoencephalopathy","volume":"152","author":"Zhai","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.nmd.2022.06.006_bib0029","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.410110227","article-title":"Progressive multifocal leukoencephalopathy in myasthenia gravis","volume":"11","author":"Dawson","year":"1982","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2022.06.006_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2008.09.019","article-title":"An unusual complication of immunosuppression in myasthenia gravis: progressive multifocal leukoencephalopathy","volume":"19","author":"Gedizlioglu","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.nmd.2022.06.006_bib0031","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","article-title":"PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents","volume":"6","author":"Kanth","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.nmd.2022.06.006_bib0032","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2022.06.006_bib0033","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"Van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.nmd.2022.06.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.nmd.2022.06.006_bib0035","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2022.06.006_bib0036","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V110.11.1288.1288","article-title":"Predictive factors to hypogammaglobulinemia and non-neutropenic infection complications after rituximab\/chemotherapy treatment","volume":"110","author":"Filanovsky","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.nmd.2022.06.006_bib0037","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology (Oxford)"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:35Z","timestamp":1760775155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0960896622001924"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.06.006","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}